Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

End Stage Renal Disease on Dialysis: later-stage trial registry

3 of 10 indexed End Stage Renal Disease on Dialysis trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count

End Stage Renal Disease on Dialysis: 10 US clinical trials tracked, 3 recruiting.

End Stage Renal Disease on Dialysis is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Vanderbilt University Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition end-stage-renal-disease-on-dialysis

OPEN 3 | RECR 30% | LATE 2 | EARLY 0 | RANK #1724 | SPON 2

Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%End Stage Renal Disease (th…30%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near End Stage Renal Disease on Dialysis

End Stage Renal Disease on Dialysis lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for End Stage Renal Disease on Dialysis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. End Stage Renal Disease on Dialysis is recruiting below its size-band peers.

    3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates End Stage Renal Disease on Dialysis research.

    Vanderbilt University Medical Center accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most End Stage Renal Disease on Dialysis trials plan to enrol fewer than 100 people.

    Median target enrolment is 41 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. End Stage Renal Disease on Dialysis research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 42

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 90 participants

Comparing Surgical and Endovascular Arteriovenous Fistula Creation

University of California, Los Angeles

NCT05654103

RECRUITING NA 40 participants

Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD

University of Illinois at Chicago

NCT07014111

RECRUITING Phase 4 30 participants

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Yale University

NCT05671991

ACTIVE NOT RECRUITING NA 200 participants

The Home Blood Pressure (BP) Trial

University of Washington

NCT05159999

ACTIVE NOT RECRUITING NA 176 participants

MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence

Vanderbilt University Medical Center

NCT05735743

ACTIVE NOT RECRUITING Phase 4 43 participants

DIALYSIS-TIR Study

University of Texas Southwestern Medical Center

NCT06042153

COMPLETED NA 41 participants

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

Outset Medical

NCT05947708

COMPLETED 36 participants

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

Sanifit Therapeutics S. A.

NCT04487301

COMPLETED NA 30 participants

Motivational Strategies To Empower African Americans To Improve Dialysis Adherence

Vanderbilt University Medical Center

NCT05003115

COMPLETED NA 12 participants

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

Diality

NCT06581393

Phase Distribution

PhaseTrial count
Phase 4 2

Named interventions

Most-linked intervention names on End Stage Renal Disease on Dialysis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Motivational interviewing Behavioral
2 trials
Dialysate Flow Rate Device
1 trials
Moda-flx Hemodialysis System Device
1 trials
Anti-hypertensive medications Drug
1 trials
Dry weight target adjustment Other
1 trials
surgAVF Procedure
1 trials
endoAVF Device
1 trials
Empagliflozin 25 mg vs Placebo Drug
1 trials

US sites by state

Facility locations filed on End Stage Renal Disease on Dialysis trials. A trial with sites in several states counts in each.

California 5 trials
Texas 2 trials
Tennessee 2 trials
Pennsylvania 2 trials
North Carolina 2 trials
Washington 1 trials
Missouri 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this End Stage Renal Disease on Dialysis page

10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This End Stage Renal Disease on Dialysis condition card totals 10 registered trials; most-linked intervention Motivational interviewing; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.